That study has shown PD-L1 expression in 65/162 (40%) patients with a trend towards improved outcomes with higher levels of PD-L1 expression [9], suggesting that a reliable determination of PD-L1 positivity is of great clinical importance when selecting treatments with PD-L1 inhibitors for patients with gastric cancer. Here, CD274 is linked to gastric cancer.